PFO
DNLI icon

Pathstone Family Office’s Denali Therapeutics DNLI Stock Holding History

Pathstone Family Office’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,000
Closed -$24K – 843
2020
Q2 		$24K Hold
1,000
– – ﹤0.01% 403
2020
Q1 		$18K Buy
+1,000
New +$20.9K ﹤0.01% 427

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pathstone Family Office's DNLI Position: Q3 2020 in Review

Pathstone Family Office sold out of Denali Therapeutics (DNLI) in Q3 2020, closing a stake of 1,000 shares — an estimated $24K sold.

Pathstone Family Office first reported a position in DNLI in Q1 2020 and held it in 2 quarters. The position peaked at $24K in Q2 2020. 170 funds tracked by Wall St. Rank hold DNLI as of Q3 2020.

  • Pathstone Family Office reported no remaining Denali Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Pathstone Family Office sold 1,000 Denali Therapeutics shares in Q3 2020, an estimated $24K.
  • Pathstone Family Office first reported a position in Denali Therapeutics in Q1 2020 and held it in 2 quarters.
  • Pathstone Family Office's Denali Therapeutics position peaked at $24K in Q2 2020.
  • 170 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2020.

Based on Pathstone Family Office's 13F filing for Q3 2020, filed 12 Nov 2020.